12/1
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
07:00 am
kpti
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
11/28
11:36 am
kpti
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]
Low
Report
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]
11/11
11:11 am
kpti
What Recent Analyst Forecasts Mean for the Changing Story Behind Karyopharm Therapeutics [Yahoo! Finance]
Medium
Report
What Recent Analyst Forecasts Mean for the Changing Story Behind Karyopharm Therapeutics [Yahoo! Finance]
11/8
07:05 pm
kpti
Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/6
06:09 pm
kpti
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight [Yahoo! Finance]
Low
Report
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight [Yahoo! Finance]
11/4
11:54 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
11/3
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
07:00 am
kpti
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Low
Report
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
10/27
07:00 am
kpti
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Low
Report
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
10/13
08:07 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Medium
Report
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
10/9
10:36 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $12.00 price target on the stock, down previously from $15.00.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $12.00 price target on the stock, down previously from $15.00.
10/9
08:09 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Robert W. Baird from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Robert W. Baird from $25.00 to $21.00. They now have an "outperform" rating on the stock.
10/8
07:11 am
kpti
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis [Yahoo! Finance]
High
Report
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis [Yahoo! Finance]
10/8
07:00 am
kpti
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Medium
Report
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
10/1
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/25
01:08 pm
kpti
Collaboration with partners drives successful clinical trials, says Bayer exec [Yahoo! Finance]
Low
Report
Collaboration with partners drives successful clinical trials, says Bayer exec [Yahoo! Finance]
9/24
05:26 am
kpti
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? [Yahoo! Finance]
High
Report
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? [Yahoo! Finance]
9/10
07:21 am
kpti
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis [Yahoo! Finance]
Medium
Report
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis [Yahoo! Finance]
9/10
07:00 am
kpti
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Low
Report
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis